ClinicalTrials.gg
CompletedNCT00707174Updated Jul 31, 2013Results posted

Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna

An interventional study of Imiquimod Cream and Tazarotene Cream 0.1% in Cancer and Lentigo Maligna, sponsored by University of Utah. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-07-31.

Sponsored by University of Utah · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed as a randomized, prospective study to test the efficacy of imiquimod plus tazarotene in the treatment of LM. Eligible and consented patients will be randomized to one of two treatment groups: 1) topical imiquimod group, or 2) topical imiquimod combined with topical tazarotene group. All patients will undergo a staged surgical excision with rush permanent sections to confirm negative histologic margins. This will be followed by a surgical repair of the defect and long-term follow-up of five years to rule out recurrences. Both groups will have a polygonal excision using 2mm margins per stage.

Read the detailed description

Objectives

The objectives of the study are:

  1. reduce the surgical morbidity of staged excisions which often require multiple stages of surgery in order to verify negative histologic margins
  2. investigate the addition of a topical retinoid, to our standard-of-care (topical imiquimod and staged-excision) and evaluate if there is improvement in efficacy
  3. to see if treatment of surrounding normal appearing skin with this combination of topical agents reduces recurrence rates compared to staged-excision. Our hypothesis is that the combination of topical agents will better treat the subclinical melanocytic atypia which can give rise to recurrences.

Primary endpoint:

The primary goal is a comparison of the number of stages required for negative histologic margins in the imiquimod plus tazarotene group compared to the imiquimod group. Tumors requiring 5 or more stages in will be combined into one category for data analysis. The Wilcoxon-Mann-Whitney test will be used for statistical comparison.

Secondary endpoints:

  1. Comparison of the surgical defect size (mm2) between the study groups. The difference in area between the entire surgical defect and the original tumor (as recorded on transparent plastic) will be calculated for each patient and used as an endpoint.
  2. Comparison of skin inflammation between the study groups. Skin inflammation will be recorded as an ordered categorical variable with four categories (0-3) as described in Section 5.
  3. The type of surgical repair required (i.e. primary repair, skin flap, skin graft).
  4. Immunostaining to evaluate inflammatory infiltrate. Immunostaining will be analyzed as an ordered categorical variable.
  5. Recurrence of the tumor at 3 months, 6 months, 12 months, and yearly for the next four years.
  6. The proportion of patients with skin ulceration.
  7. The relationship between ulceration, skin inflammation and clearance of LM.

Study Procedures A total of eighty patients, over a twelve-month period, will be recruited from one center for this open label study. Forty patients will be randomly assigned to one of two treatment groups as mentioned in the Study Design section. The study will consist of 4 phases: (1) Enrollment and screening period to evaluate skin cancer, measure and trace its perimeter; (2) 12 week treatment with topical application of study drug(s); (3) Surgical excision of treatment site to ensure eradication of the tumor; (4) Follow-up period to rule out recurrences.

All patients must have a biopsy-proven diagnosis of lentigo maligna confirmed by at least two dermatopathologists from the Department of Dermatology at the University of Utah School of Medicine. At the initial examination the clinical borders of the lesion will be defined using a Wood's lamp (360nm) and the perimeter will be outlined with a gentian violet marker and photographed for the medical record. (Wood's lamp examination helps to identify pigmentary alterations of the skin when are sometimes difficult to appreciate under normal lighting conditions.) At the time of enrollment, to rule out an invasive melanoma, all potential study participants will undergo a shave biopsy of their lesion using local anesthesia. Enrollment will not occur until the biopsy has been examined and confirmed to be a lentigo maligna (melanoma in-situ). If an invasive melanoma is found, the patient will be excluded from the study and additional evaluation/therapies implemented. If the patient is enrolled in the study, a piece of their biopsy specimen will be used to perform immunohistochemistry to evaluate the inflammatory infiltrate. A similar series of histochemical staining will be performed at the conclusion of the study using a piece of the excised skin.

Topical imiquimod group:

Patients randomized to this group will have the perimeter of the LM site, as defined by a Wood's lamp examination, drawn on the skin with a gentian violet pen and photographed with a Polaroid camera . One photograph will go to the medical record and the second given to the patient to help identify the proposed treatment area. The gentian violet perimeter will then be copied on transparent plastic to facilitate tumor localization since the tumor is predicted to disappear clinically during treatment. The patients will then treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site. A staged excision will then be performed with two millimeter margins around the original tumor perimeter as previously recorded on transparent plastic which will be placed on the patient's skin to outline the perimeter accurately. Once negative margins are confirmed histologically, post-operative defect size will be measured in mm2 and then a plastic surgical repair will be performed to optimize cosmesis.

Topical imiquimod and topical tazarotene 0.1% cream group:

Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week.

02

Conditions studied

  • Cancer
  • Lentigo Maligna

Browse trials for

Keywords

  • Lentigo Maligna
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Utah is the lead sponsor of 997 studies on the registry; 176 are open to participants now.

Of its 114 completed or terminated interventional studies of FDA-regulated products, 69 (61%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The study population will consist of eighty subjects who are 18 years or older and have a -proven lentigo maligna.
  • The subjects must have a LM that is in a location amenable to treatment with imiquimod, express a willingness and ability to comply with study requirements, and tolerate an outpatient surgical procedure.
  • All participants will sign consent documents prior to enrollment.
  • The typical age of patient that develops a LM is beyond the child-bearing range.

Exclusion criteria

Exclusion Criteria:

  • In the event that a patient with a LM is pregnant, they will be excluded from the study.
  • inability to tolerate the surgical procedure
  • invasive melanoma
  • previous surgery on the site of interest
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    1

    Topical imiquimod group: treat the LM site two centimeters beyond the perimeter margin with topical imiquimod 5% cream Monday thru Friday of each week for a total of twelve weeks. After three months of topical treatment, a one-month wash out period will be observed to allow for resolution of inflammation that can obscure the pathologist's ability to evaluate the excised tumor/treatment site.

    Drug: Imiquimod Cream

  • Experimental
    2

    Topical imiquimod and topical tazarotene 0.1% cream group: Patients randomized to this group will undergo an identical treatment protocol as the topical imiquimod group with the addition of topical tazarotene 0.1% cream on Saturday and Sunday of each week.

    Drug: Tazarotene Cream 0.1%

Interventions

  • DrugImiquimodStudies of ImiquimodImiquimod pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve

  • DrugTazaroteneStudies of TazaroteneTazarotene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.

06

What researchers measure

Primary outcomes

  1. The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants

    Negative histologic margins for the imiquimod plus tazarotene group compared to the imiquimod only group.

    Time frame: 24 months

07

Results

Posted Aug 20, 2012

Participant flow

Participant flow — Overall Study
MilestoneImiquimod OnlyImiquimod and Tazarotene Combined
Started4644
Completed4137
Not completed57
Withdrew: Adverse event16
Withdrew: Withdrawal by subject41

Outcome measures

PrimaryThe Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants

Negative histologic margins for the imiquimod plus tazarotene group compared to the imiquimod only group.

Time frame:
24 months
Reported as:
Number · participants
The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants
participantsImiquimod OnlyImiquimod and Tazarotene Combined
The Absence of Lentigo Maligna (LM) at the Time of Staged Excisions in Participants2729

Adverse events

Collected over 5 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imiquimod Only—0/46 (0%)1/46 (2.2%)
Imiquimod and Tazarotene Combined—0/44 (0%)6/44 (13.6%)
Most frequent other events
Most frequent other events
EventImiquimod OnlyImiquimod and Tazarotene Combined
Inflammatory ResponseSkin and subcutaneous tissue disorders1/466/44

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Imiquimod OnlyImiquimod and Tazarotene CombinedTotal
<=18 years000
Between 18 and 65 years211637
>=65 years252853
Age Continuous
Age Continuous(years)Imiquimod OnlyImiquimod and Tazarotene CombinedTotal
Mean67.87234 ± 13.0760667.40909 ± 11.9928667.64 ± 12.49655
Sex: Female, Male
Sex: Female, Male(Participants)Imiquimod OnlyImiquimod and Tazarotene CombinedTotal
Female111324
Male353166
Region of Enrollment
Region of Enrollment(participants)Imiquimod OnlyImiquimod and Tazarotene CombinedTotal
United States464490
08

Study locations

1 site
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
09

References and documents

Publications

  • Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012 May;148(5):592-6. doi: 10.1001/archdermatol.2012.270. PubMed 22431716 ↗
  • Ho PA, Kopecky KJ, Alonzo TA, Gerbing RB, Miller KL, Kuhn J, Zeng R, Ries RE, Raimondi SC, Hirsch BA, Oehler V, Hurwitz CA, Franklin JL, Gamis AS, Petersdorf SH, Anderson JE, Godwin JE, Reaman GH, Willman CL, Bernstein ID, Radich JP, Appelbaum FR, Stirewalt DL, Meshinchi S. Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the Children's Oncology Group and SWOG. Blood. 2011 Oct 27;118(17):4561-6. doi: 10.1182/blood-2011-04-348888. Epub 2011 Aug 26. PubMed 21873548 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2008
First posted
Jun 30, 2008
Start
Mar 2005
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Aug 20, 2012
Last update
Jul 31, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00707174
Lead sponsor
University of Utah
Responsible party
Sponsor
First posted
Jun 30, 2008
Start date
Mar 2005
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Aug 20, 2012
Last update
Jul 31, 2013

Study contacts

Glen Bowen, MD
principal investigator · Huntsman Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tazarotene

Start the discussion